Conmed Corporation CNMD
Margin expanding Guidance confirmed Revenue accelerating ◦
The new quarter, monitored by AI. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
ConMed Corporation is a medical device company that develops, manufactures, and markets surgical products for use by healthcare professionals across two reporting segments. The orthopedic surgery segment encompasses sports medicine devices, powered instruments, and related capital equipment, while the general surgery segment centers on advanced energy devices, insufflation systems including the AirSeal platform, and related surgical tools; the company exited its gastroenterology product line in 2025-2026 as part of a portfolio optimization strategy. Revenue is generated through direct sales to hospitals and ambulatory surgery centers in the United States and through a combination of direct sales forces and distributor networks in international markets, with capital equipment placements typically followed by recurring consumable and single-use device purchases.
Advertisement
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
ConMed reported Q2 2026 net sales of $343.5M, a 0.3% increase year-over-year as reported, with the orthopedic surgery segment advancing 8.2% in the quarter 30. Reported diluted EPS was $0.77 and adjusted diluted EPS was $1.38, the latter up 20.0% year-over-year 31. The company updated its full-year 2026 guidance to net sales of $1,358–$1,373M, organic constant currency growth of 5.0–6.0%, and adjusted diluted EPS of $4.48–$4.60 31. John E. Gallagher was appointed Chief Financial Officer effective July 15, 2026, and Celine Martin and Jeff Mirviss joined the Board of Directors effective July 1, 2026 31.
Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-07-29):
„We are updating our financial guidance for the full year 2026 today to reflect both our second quarter performance and our updated outlook for the balance of the year. Looking ahead, our team remains focused on disciplined execution as we continue to position CONMED for quality, long-term growth and value creation.“ – Patrick J. Beyer, President and Chief Executive Officer 31
„We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations. Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace. In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team.“ – Patrick J. Beyer, President and Chief Executive Officer 31
Revenue · 2026-Q2344$m+0.4 % vs. 2025-Q2
Net profit · 2026-Q223$m+7.9 % vs. 2025-Q2
EPS · 2026-Q20.77$+11.6 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, the company guides EPS (non-GAAP) to $4.48 to $4.60 (raised); Net Sales Growth, as reported to (1.2)% to (0.1)% (confirmed); Net Sales Growth, Constant Currency to (1.7)% to (0.7)% (confirmed). 31.
ProfitabilityOperating income was $36.4M and net income was $23.1M in Q2 2026, with net income representing 6.7% of net sales, up from 6.3% in Q2 2025 30 31. Adjusted diluted EPS of $1.38 included a $0.21 per share benefit from IEEPA tariff refunds received during the quarter 31. Gross profit margin increased 250 basis points to 57.5% in Q2 2026, with the first-half 2026 gross margin reaching 57.7% 30.
LeverageCash stood at $37.3M and net debt at $619.7M at the end of Q2 2026 31. During the quarter, the company repurchased $645.2M principal amount of its 2.250% Convertible Notes for $637.2M in cash, effecting a partial debt refinancing 30. Operating cash flow for the six months ended June 30, 2026 was $50.6M, compared to $70.7M in the prior-year period 30.
Management viewFull-year 2026 guidance was updated to net sales of $1,358–$1,373M and adjusted diluted EPS of $4.48–$4.60, reflecting the company's expectations after the gastroenterology exit and ongoing segment performance 31. The AirSeal Robotic Solution received a new indication for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform, announced July 22, 2026, extending the product's compatibility within robotic-assisted surgery 31. Portfolio optimization was cited as the strategic rationale for completing the exit from gastroenterology product offerings during the period 30 31.
ChangeGeneral surgery segment sales decreased 5.2% in Q2 2026, primarily driven by the exit from gastroenterology product offerings, with the six-month decline at 6.2% 30. Domestic sales decreased 8.0% as reported in Q2 2026 31. Q2 2026 net sales on a constant currency basis declined 0.5%, and net sales for the six months ended June 30, 2026 also decreased 0.5% as reported compared to the prior-year period 30 31.
Risks (current)Trade protection measures, tariffs, and border taxes represent a company-specific operational risk, with continued tariff exposure affecting results 30. EU Medical Device Regulation compliance costs were incurred in Q2 2026, and the potential unavailability of EtO sterilization poses an additional regulatory and operational risk 30 31. The gastroenterology product line exits affect period-over-period comparability, and the company faces ongoing exposure to patent, product, and other litigation costs 29 31.
New this reporting periodIn Q2 2026, ConMed completed the sale of additional gastroenterology assets, recorded as a business sale, and entered into a manufacturing and supply agreement for gastroenterology products as part of the broader portfolio exit 30. The AirSeal Robotic Solution received a new indication for use with Intuitive's 8 mm hex cannulas as part of the da Vinci 5 platform, with the indication announced on July 22, 2026 31. Biorez acquisition contingent consideration payments were also made during the first half of 2026 30.
Advertisement
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
Portfolio reshaping: Orthopedic Surgery growth and AirSeal/BioBrace traction offsetting the exit from gastroenterology
Orthopedic Surgery grew +6.8% while General Surgery fell -7.4% as gastroenterology product lines were divested, so the mix shift toward faster-growing lines drives group revenue and margin direction; group revenue rose to 343.5 in 2026-Q2 with adj_EPS 1.38 vs 1.15 a year earlier 29 31
Orthopedic Surgery grew +6.8% while General Surgery fell -7.4% as gastroenterology product lines were divested, so the mix shift toward faster-growing lines drives group revenue and margin direction; group revenue rose to 343.5 in 2026-Q2 with adj_EPS 1.38 vs 1.15 a year earlier 29 31
Orthopedic Surgery segment (BioBrace sports medicine)
Orthopedic Surgery revenue 147.7 in 2026-Q1, +6.8%, the fastest-growing segment, supported by BioBrace product growth 29 17
Orthopedic Surgery revenue 147.7 in 2026-Q1, +6.8%, the fastest-growing segment, supported by BioBrace product growth 29 17
AirSeal robotic-surgery franchise
AirSeal Robotic Solution received an indication for the Intuitive da Vinci 5 platform (2026-07-22) and prior AirSeal product-offering expansion signals continued traction 31 17
AirSeal Robotic Solution received an indication for the Intuitive da Vinci 5 platform (2026-07-22) and prior AirSeal product-offering expansion signals continued traction 31 17
General Surgery / gastroenterology exit
General Surgery revenue 169.3 in 2026-Q1, -7.4%, reflecting strategic exits and divestitures of the gastroenterology portfolio and termination of the Gore VIABIL biliary distribution agreement 29 30
General Surgery revenue 169.3 in 2026-Q1, -7.4%, reflecting strategic exits and divestitures of the gastroenterology portfolio and termination of the Gore VIABIL biliary distribution agreement 29 30
International vs Domestic geographic mix
International revenue 144.0 grew +4.7% while Domestic 173.0 declined -5.8% in 2026-Q1, shifting growth contribution abroad 28
International revenue 144.0 grew +4.7% while Domestic 173.0 declined -5.8% in 2026-Q1, shifting growth contribution abroad 28
Capital Products
Capital Products revenue 47.0 in 2026-Q1, +4.6%; single-use products 270.0 were roughly flat at -2.3% 29
Capital Products revenue 47.0 in 2026-Q1, +4.6%; single-use products 270.0 were roughly flat at -2.3% 29
Deleveraging and debt structure
Repurchase of $645.2 million principal of 2.250% Convertible Notes in 2026-Q2; net debt reduced from 856.0 (2025-Q1) toward 619.7 (2026-Q2) 30 31
Repurchase of $645.2 million principal of 2.250% Convertible Notes in 2026-Q2; net debt reduced from 856.0 (2025-Q1) toward 619.7 (2026-Q2) 30 31
Sector trend: Group profitability is improving with the change flags showing accelerating growth, higher profitability and raised guidance, as adj_EPS rose to 1.38 in 2026-Q2 from 1.15 a year earlier 31. Demand is skewing toward orthopedic/sports-medicine and robotic-surgery consumables while lower-growth gastroenterology lines are being exited 29 30.
Advertisement
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
Overview: one dot per event · click jumps to the period
2026 · 7 events
2026-Q2 · Apr – Jun 2026
„We are updating our financial guidance for the full year 2026 today to reflect both our second quarter performance and our updated outlook for the balance of the year. Looking ahead, our team remains focused on disciplined execution as we continue to position CONMED for quality, long-term growth and value creation.“ – Patrick J. Beyer, President and Chief Executive Officer 31
Revenue accelerating ◦ 2026-07-29
Orthopedic surgery segment sales grew 8.2% in Q2 2026; excluding gastroenterology exits, company-wide organic constant currency sales grew 6.0% 30 31
Orthopedic surgery segment sales grew 8.2% in Q2 2026; excluding gastroenterology exits, company-wide organic constant currency sales grew 6.0% 30 31
Guidance confirmed 2026-07-29
Full-year 2026 guidance updated to net sales $1,358-$1,373 million, organic constant currency growth 5.0%-6.0% (top end narrowed from prior 6.5%), and adjusted diluted EPS $4.48-$4.60 31
Full-year 2026 guidance updated to net sales $1,358-$1,373 million, organic constant currency growth 5.0%-6.0% (top end narrowed from prior 6.5%), and adjusted diluted EPS $4.48-$4.60 31
2026-Q1 · Jan – Mar 2026
„Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations. We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.“ – Patrick J. Beyer, President and Chief Executive Officer 28
Margin expanding 2026-04-30
Gross profit margin expanded 260 basis points to 57.9%, driven by Gore distribution termination benefit, favorable foreign currency impact, and product mix 29
Gross profit margin expanded 260 basis points to 57.9%, driven by Gore distribution termination benefit, favorable foreign currency impact, and product mix 29
Strategic pivot 2026-04-30
Exited gastroenterology product lines including termination of Gore VIABIL biliary stent distribution effective January 1, 2026, reducing Q1 reported domestic revenue by $15.2M and total sales by $15.5M 29
Exited gastroenterology product lines including termination of Gore VIABIL biliary stent distribution effective January 1, 2026, reducing Q1 reported domestic revenue by $15.2M and total sales by $15.5M 29
Guidance raised 2026-04-29
Full-year 2026 organic constant currency revenue growth guidance raised to 5.0%-6.5% from prior 4.5%-6.0%; reported revenue guidance raised to $1.350-$1.375 billion 28
Full-year 2026 organic constant currency revenue growth guidance raised to 5.0%-6.5% from prior 4.5%-6.0%; reported revenue guidance raised to $1.350-$1.375 billion 28
2025 · 18 events
FY2025 · Jan – Dec 2025
2025-Q4 · Oct – Dec 2025
„Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives. As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long‑term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.“ – Patrick J. Beyer, President and Chief Executive Officer 26
Divestiture 2026-02-17
Company announced December 5, 2025 intent to exit gastroenterology product lines; accelerated termination of Gore VIABIL biliary stent distribution agreement to January 1, 2026 as part of portfolio optimization strategy 27
Company announced December 5, 2025 intent to exit gastroenterology product lines; accelerated termination of Gore VIABIL biliary stent distribution agreement to January 1, 2026 as part of portfolio optimization strategy 27
Revenue accelerating 2026-01-28
Q4 net sales +7.9% YoY (+7.1% constant currency) to $373.2M; international revenue +17.0% as reported and +15.4% in constant currency; full-year 2025 revenue +5.2% to $1,374.7M 26
Q4 net sales +7.9% YoY (+7.1% constant currency) to $373.2M; international revenue +17.0% as reported and +15.4% in constant currency; full-year 2025 revenue +5.2% to $1,374.7M 26
Guidance initiated 2026-01-28
2026 full-year guidance initiated: revenue $1.345-$1.375B (4.5%-6% organic constant currency growth); adjusted diluted EPS $4.30-$4.45 including approximately $0.10 currency tailwind 26
2026 full-year guidance initiated: revenue $1.345-$1.375B (4.5%-6% organic constant currency growth); adjusted diluted EPS $4.30-$4.45 including approximately $0.10 currency tailwind 26
2025-Q3 · Jul – Sep 2025
„We are pleased with our third quarter performance, which reflects continued progress in strengthening our supply chain and strong execution across our core growth platforms. We are building on this momentum in the fourth quarter and beyond, supported by our portfolio of best-in-class clinical solutions, operational discipline, and commitment to innovation.“ – Patrick J. Beyer, President and Chief Executive Officer 24
Margin compressing 2025-11-06
Gross profit margin declined 730bps to 49.2% in Q3, driven by $19.7M in inventory write-offs for cancelled product lines and tariff costs 25
Gross profit margin declined 730bps to 49.2% in Q3, driven by $19.7M in inventory write-offs for cancelled product lines and tariff costs 25
Revenue accelerating 2025-11-05
Q3 net sales +6.7% YoY (+6.3% constant currency) to $337.9M; domestic +5.9%, international +7.8% as reported 24
Q3 net sales +6.7% YoY (+6.3% constant currency) to $337.9M; domestic +5.9%, international +7.8% as reported 24
Strategic pivot 2025-11-05
Board authorized $150M share repurchase program and suspended quarterly cash dividend; company anticipates repurchasing at least $25M in shares annually beginning in 2026 24
Board authorized $150M share repurchase program and suspended quarterly cash dividend; company anticipates repurchasing at least $25M in shares annually beginning in 2026 24
Operating income halved 2025-11-05
Operating income more than halved YoY (65.7 to 11.9 USDm, -82%). 24
Operating income more than halved YoY (65.7 to 11.9 USDm, -82%). 24
2025-Q2 · Apr – Jun 2025
„We are encouraged by our second quarter performance as we focused on building a stronger operational foundation. We continue to strengthen our supply chain operations with a focus on turning this into an area of strength within CONMED. We remain very confident in the long-term potential of our four key growth drivers and the solid foundation for sustained revenue and earnings growth that they provide.“ – Patrick J. Beyer, President and Chief Executive Officer 22
Margin compressing 2025-07-31
Gross profit margin declined 30bps to 55.0% due to consulting charges for supply chain and manufacturing improvements and inventory write-offs, partially offset by favorable product mix 23
Gross profit margin declined 30bps to 55.0% due to consulting charges for supply chain and manufacturing improvements and inventory write-offs, partially offset by favorable product mix 23
revenue 2025-07-30
Q2 net sales +3.1% YoY to $342.3M; Single-use Products segment +6.6%, Capital Products revenue -15.5% 22
Q2 net sales +3.1% YoY to $342.3M; Single-use Products segment +6.6%, Capital Products revenue -15.5% 22
Guidance raised 2025-07-30
Full-year adjusted diluted EPS guidance raised to $4.40-$4.55 from prior $4.31-$4.46; revenue range narrowed to $1.356-$1.378B with foreign currency headwinds now expected to be immaterial 22
Full-year adjusted diluted EPS guidance raised to $4.40-$4.55 from prior $4.31-$4.46; revenue range narrowed to $1.356-$1.378B with foreign currency headwinds now expected to be immaterial 22
2025-Q1 · Jan – Mar 2025
„We had a good start to 2025, which positions us well to achieve our full-year guidance. I am proud of our team's dedication to strengthening our operations in order to better support our key growth platforms and drive long-term shareholder value.“ – Patrick J. Beyer, President and Chief Executive Officer 20
earnings 2025-05-01
GAAP diluted EPS fell to $0.19 from $0.63 in Q1 2024; S&A expenses rose 680bps to 46.3% of sales, driven by $12.2M in CEO advisory compensation and $10.5M net contingent consideration fair value expense – not operational deterioration 21
GAAP diluted EPS fell to $0.19 from $0.63 in Q1 2024; S&A expenses rose 680bps to 46.3% of sales, driven by $12.2M in CEO advisory compensation and $10.5M net contingent consideration fair value expense – not operational deterioration 21
revenue 2025-04-30
Q1 net sales +2.9% YoY (+3.8% constant currency) to $321.3M; domestic +4.2%, international +1.2% as reported, with growth across orthopedic and general surgery product lines 20
Q1 net sales +2.9% YoY (+3.8% constant currency) to $321.3M; domestic +4.2%, international +1.2% as reported, with growth across orthopedic and general surgery product lines 20
Guidance raised 2025-04-30
Full-year revenue guidance raised to $1.350-$1.378B from $1.344-$1.372B; adjusted diluted EPS guidance raised to $4.45-$4.60 from $4.25-$4.40; FX headwind revised to 50-70bps from 100-120bps 20
Full-year revenue guidance raised to $1.350-$1.378B from $1.344-$1.372B; adjusted diluted EPS guidance raised to $4.45-$4.60 from $4.25-$4.40; FX headwind revised to 50-70bps from 100-120bps 20
Operating income halved 2025-04-30
Operating income more than halved YoY (35.0 to 16.0 USDm, -54%). 20
Operating income more than halved YoY (35.0 to 16.0 USDm, -54%). 20
2024 · 19 events
FY2024 · Jan – Dec 2024
2024-Q4 · Oct – Dec 2024
„2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability. In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.“ – Patrick J. Beyer, President and Chief Executive Officer 18
earnings 2025-02-05
Q4 adjusted diluted EPS increased 26.4% to $1.34; full-year adjusted diluted EPS rose 20.9% to $4.17 and adjusted EBITDA grew to $265.6 million from $235.4 million in 2023 18
Q4 adjusted diluted EPS increased 26.4% to $1.34; full-year adjusted diluted EPS rose 20.9% to $4.17 and adjusted EBITDA grew to $265.6 million from $235.4 million in 2023 18
Revenue accelerating 2025-02-05
Q4 net sales increased 5.8% year-over-year to $345.9 million (6.0% constant currency), re-accelerating from the 4.0% growth rate in Q3 2024; Single-use Products segment grew 9.6% in Q4 18
Q4 net sales increased 5.8% year-over-year to $345.9 million (6.0% constant currency), re-accelerating from the 4.0% growth rate in Q3 2024; Single-use Products segment grew 9.6% in Q4 18
2024-Q3 · Jul – Sep 2024
„Our third quarter results were largely in line with our expectations, and we remain focused on getting fully back on offense. I am particularly proud of how our teams responded to the disruption from hurricanes Helene and Milton, which temporarily impacted our employees and facilities in the Southeast as well as many of our customers.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 16
Margin expanding 2024-10-31
Gross profit margin expanded 130 basis points to 56.5% in Q3 2024, primarily due to favorable product mix 17
Gross profit margin expanded 130 basis points to 56.5% in Q3 2024, primarily due to favorable product mix 17
Guidance raised 2024-10-30
Full-year adjusted diluted EPS guidance raised to $4.00-$4.05 from prior range of $3.95-$4.02, while full-year revenue guidance was modestly reduced to $1.300-$1.305 billion 16
Full-year adjusted diluted EPS guidance raised to $4.00-$4.05 from prior range of $3.95-$4.02, while full-year revenue guidance was modestly reduced to $1.300-$1.305 billion 16
Strategic pivot 2024-10-30
COO Patrick Beyer announced as successor to President and CEO Curt Hartman, effective January 1, 2025, upon Mr. Hartman's retirement 16
COO Patrick Beyer announced as successor to President and CEO Curt Hartman, effective January 1, 2025, upon Mr. Hartman's retirement 16
Operating income doubled 2024-10-30
Operating income more than doubled YoY (30.3 to 65.7 USDm, +117%). 16
Operating income more than doubled YoY (30.3 to 65.7 USDm, +117%). 16
2024-Q2 · Apr – Jun 2024
„Our second quarter and first half of 2024 played out largely as expected. Looking forward, we have not yet fully recovered from our supply chain challenges, which has delayed the commercial reacceleration that we had contemplated in our plan at the beginning of the year. We remain highly focused on getting back on offense to serve our customers and driving above-market, long-term growth.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 13
revenue 2024-07-31
Q2 net sales increased 4.5% year-over-year to $332.1 million (5.2% constant currency), decelerating from the 5.7% growth rate in Q1 2024 13
Q2 net sales increased 4.5% year-over-year to $332.1 million (5.2% constant currency), decelerating from the 5.7% growth rate in Q1 2024 13
Margin expanding 2024-07-31
Gross profit margin improved 160 basis points to 55.3% in Q2 2024, due to favorable product mix and the absence of In2Bones inventory step-up amortization costs that were present in the prior-year period 13 14
Gross profit margin improved 160 basis points to 55.3% in Q2 2024, due to favorable product mix and the absence of In2Bones inventory step-up amortization costs that were present in the prior-year period 13 14
Guidance cut 2024-07-31
Full-year revenue guidance cut to $1.305-$1.315 billion and adjusted diluted EPS guidance reduced to $3.95-$4.02, as supply chain challenges delayed previously anticipated commercial reacceleration 13
Full-year revenue guidance cut to $1.305-$1.315 billion and adjusted diluted EPS guidance reduced to $3.95-$4.02, as supply chain challenges delayed previously anticipated commercial reacceleration 13
2024-Q1 · Jan – Mar 2024
„2024 is off to a solid start as the quarter delivered our expected top- and bottom-line growth and margin expansion. We remain well positioned with a compelling and diverse portfolio to drive continued growth across the markets we serve.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 11
revenue 2024-04-24
Q1 net sales increased 5.7% year-over-year to $312.3 million (5.9% constant currency), led by growth in orthopedic surgery and general surgery product lines 11
Q1 net sales increased 5.7% year-over-year to $312.3 million (5.9% constant currency), led by growth in orthopedic surgery and general surgery product lines 11
Margin expanding 2024-04-24
Gross profit margin expanded 250 basis points to 55.1% from 52.6% in Q1 2023, driven by favorable product mix 11 12
Gross profit margin expanded 250 basis points to 55.1% from 52.6% in Q1 2023, driven by favorable product mix 11 12
Guidance cut 2024-04-24
Full-year revenue guidance lowered to $1.330-$1.355 billion and adjusted diluted EPS guidance reduced to $4.25-$4.35, citing approximately $10 million in incremental foreign currency headwinds 11
Full-year revenue guidance lowered to $1.330-$1.355 billion and adjusted diluted EPS guidance reduced to $4.25-$4.35, citing approximately $10 million in incremental foreign currency headwinds 11
Operating income doubled 2024-04-24
Operating income more than doubled YoY (12.7 to 35.0 USDm, +176%). 11
Operating income more than doubled YoY (12.7 to 35.0 USDm, +176%). 11
2023 · 13 events
2023-Q4 · Oct – Dec 2023
„2023 was a great year for CONMED, and I am proud that our global business delivered record revenue in both the fourth quarter and for the full year. The balanced growth we saw across our various businesses and geographies is a testament to the strength of the portfolio that we have built. As we shift our focus to 2024, we are very excited to continue delivering innovative technology solutions to our customers and patients across both the General Surgery and Orthopedics categories.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 9
earnings 2024-01-31
Full-year 2023 net income of $64.5M vs. net loss of $80.6M in 2022; full-year adjusted diluted EPS increased 30.2% to $3.45 9
Full-year 2023 net income of $64.5M vs. net loss of $80.6M in 2022; full-year adjusted diluted EPS increased 30.2% to $3.45 9
Revenue accelerating 2024-01-31
Q4 net sales of $327.0M grew 30.4% YoY; full-year net sales reached $1,244.7M, up 19.1% as reported and 20.9% in constant currency 9
Q4 net sales of $327.0M grew 30.4% YoY; full-year net sales reached $1,244.7M, up 19.1% as reported and 20.9% in constant currency 9
2023-Q3 · Jul – Sep 2023
„The third quarter saw our team drive double-digit revenue and earnings growth amid healthy end markets. I'm proud of what we've accomplished year to date in 2023, particularly that the team has been able to drive above-market revenue growth in both businesses.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 7
Margin expanding 2023-10-26
Quarterly gross margin expanded 10 bps to 55.2%, first YoY quarterly improvement in FY2023, as warehouse management system disruptions abated 8
Quarterly gross margin expanded 10 bps to 55.2%, first YoY quarterly improvement in FY2023, as warehouse management system disruptions abated 8
revenue 2023-10-25
Net sales grew 10.7% YoY to $304.6M, further decelerating; acquisitions contributed ~40 bps; nine-month revenue up 15.5% 7
Net sales grew 10.7% YoY to $304.6M, further decelerating; acquisitions contributed ~40 bps; nine-month revenue up 15.5% 7
Guidance raised 2023-10-25
Full-year 2023 revenue guidance lower end raised to $1.240B–$1.260B; adjusted diluted EPS lower end raised to $3.45–$3.55 7
Full-year 2023 revenue guidance lower end raised to $1.240B–$1.260B; adjusted diluted EPS lower end raised to $3.45–$3.55 7
2023-Q2 · Apr – Jun 2023
„Our team drove excellent growth across both Orthopedics and General Surgery during the second quarter, building on the momentum we generated during the first three months of the year. We remain confident in our ability to grow above market and continue to deliver clinical innovation to our customers.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 5
Margin compressing 2023-07-27
Gross margin fell 110 bps to 53.7% in Q2, driven by inflation in raw materials, freight, and production costs 6
Gross margin fell 110 bps to 53.7% in Q2, driven by inflation in raw materials, freight, and production costs 6
revenue 2023-07-26
Net sales grew 14.6% YoY to $317.7M, decelerating from 21.9% in Q1; acquisitions contributed ~400 bps 5
Net sales grew 14.6% YoY to $317.7M, decelerating from 21.9% in Q1; acquisitions contributed ~400 bps 5
Guidance raised 2023-07-26
Full-year 2023 revenue guidance raised to $1.230B–$1.260B; adjusted diluted EPS guidance raised to $3.40–$3.55 5
Full-year 2023 revenue guidance raised to $1.230B–$1.260B; adjusted diluted EPS guidance raised to $3.40–$3.55 5
2023-Q1 · Jan – Mar 2023
„I am proud of our team for driving excellent first quarter results and staying focused on serving our customers. Our strong first quarter provides a very solid start to the year, and the team is focused on execution and delivering on our increased outlook.“ – Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer 3
Margin compressing 2023-04-27
Gross margin fell 350 bps to 52.6% due to inflation and acquisition-related inventory step-up costs 4
Gross margin fell 350 bps to 52.6% due to inflation and acquisition-related inventory step-up costs 4
Revenue accelerating 2023-04-26
Net sales grew 21.9% YoY to $295.5M; In2Bones and Biorez acquisitions contributed ~570 bps of growth 3
Net sales grew 21.9% YoY to $295.5M; In2Bones and Biorez acquisitions contributed ~570 bps of growth 3
Guidance raised 2023-04-26
Full-year 2023 revenue guidance raised to $1.205B–$1.250B; adjusted diluted EPS guidance raised to $3.30–$3.50 3
Full-year 2023 revenue guidance raised to $1.205B–$1.250B; adjusted diluted EPS guidance raised to $3.30–$3.50 3
Advertisement
Key Figures ($m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue ($m) · annual basis, as reported
Net income ($m) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($m) · annual basis, as reported
Revenue ($m) · quarterly basis, as reported
Net income ($m) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($m) · quarterly basis, as reported
Cash ($m) · annual basis, as reported
Debt ($m) · annual basis, as reported
Net Debt ($m) · annual basis, as reported
Capex ($m) · annual basis, as reported
FCF ($m) · annual basis, as reported
D&A ($m) · annual basis, as reported
Cash ($m) · quarterly basis, as reported
Debt ($m) · quarterly basis, as reported
Net Debt ($m) · quarterly basis, as reported
Capex ($m) · quarterly basis, as reported
FCF ($m) · quarterly basis, as reported
D&A ($m) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2016 is on record.
Fiscal years
Amounts in $m · EPS in $ per share · as reported
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | OCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 1,374.7 | 102.6 | – | 47.1 | 1.51 | 4.59 | 275.89 | 170.7 | 27 |
| FY2024 | 1,307 | 200.3 | 202.78 | 132.4 | 4.25 | 4.17 | 265.57 | 167 | 19 |
| FY2023 | 1,244.7 | 120.6 | 174.39 | 64.5 | 2.04 | 3.45 | 235.45 | 125.3 | 10 |
Quarters
Amounts in $m · EPS in $ per share · Net Debt/EBITDA as a multiple · as reported
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | FCF | Cash | Net Debt | Net Debt/EBITDA (x) | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-07-29 | 343.5 | 36.4 | – | 23.1 | 0.77 | 1.38 | 78.1 | – | 37.3 | 619.7 | – | 30 |
| 2026-Q1* | 2026-04-29 | 317 | 25.4 | 41.5 | 13.8 | 0.44* | 0.89 | 56.4 | – | – | – | – | 28 |
| 2025-Q4* | 2026-01-28 | 373.2 | 36.6 | – | 16.7 | 0.54* | 1.43 | 80.4 | 41.2 | 40.8 | 793.4 | 5.1x (LTM) | 26 |
| 2025-Q3* | 2025-11-05 | 337.9 | 11.9 | – | 2.9 | 0.09 | 1.08 | 65.6 | 48.5 | 38.9 | 814.1 | 4.8x (LTM) | 24 |
| 2025-Q2* | 2025-07-30 | 342.3 | 38.2 | – | 21.4 | 0.69 | 1.15 | 68.6 | 23.4 | 33.9 | 847.2 | 3.8x (LTM) | 22 |
| 2025-Q1* | 2025-04-30 | 321.3 | 16 | 45.3 | 6 | 0.19 | 0.95 | 61.3 | 37.8 | 35.5 | 856 | 3.7x (LTM) | 20 |
| 2024-Q4* | 2025-02-05 | 345.9 | 52.5 | 64.5 | 33.8 | 1.08* | 1.34 | 80 | 39.3 | 24.5 | 880.6 | 3.5x (LTM) | 118 |
| 2024-Q3* | 2024-10-30 | 316.7 | 65.7 | – | 49 | 1.57 | 1.05 | 64.6 | 47.8 | 38.5 | 901.6 | 3.6x (LTM) | 16 |
| 2024-Q2* | 2024-07-31 | 332.1 | 47.1 | – | 30 | 0.96 | 0.98 | 64.6 | 39.7 | 28.9 | 936.3 | 4.4x (LTM) | 13 |
| 2024-Q1* | 2024-04-24 | 312.3 | 35 | – | 19.7 | 0.63 | 0.66 | 56.3 | 27.1 | 33.9 | 956.3 | 4.9x (LTM) | 11 |
| 2023-Q4* | 2024-01-31 | 327 | 50.2 | 51.8 | 33.1 | 1.05* | 0.42 | 66.9 | 51.5 | 24.3 | 948.8 | 5.5x (LTM) | 109 |
| 2023-Q3* | 2023-10-25 | 304.6 | 30.3 | – | 15.8 | 0.50 | 0.77 | 59.7 | 40.7 | 30.5 | 911.7 | 7.6x (LTM) | 7 |
| 2023-Q2* | 2023-07-26 | 317.7 | 27.4 | – | 13.7 | 0.43 | 0.76 | 57.6 | 22.1 | 27.8 | 943.6 | 8.2x (LTM) | 5 |
| 2023-Q1* | 2023-04-26 | 295.5 | 12.7 | – | 1.8 | 0.06 | 0.66 | 51.2 | -8.1 | 26.5 | 968.8 | 8.7x (LTM) | 3 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Advertisement
Balance Sheet & Cash Flow ($m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
Amounts in $m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-01-28 | 40.8 | 834.2 | 793.4 | 52.3 | 170.7 | 19.8 | 150.9 | 26 |
| FY2024 | 2025-02-05 | 24.5 | 905.1 | 880.6 | 51.3 | 167 | 13.1 | 153.9 | 18 |
| FY2023 | 2024-01-31 | 24.3 | 973.1 | 948.8 | 51.4 | 125.3 | 19 | 106.3 | 9 |
Quarters
Amounts in $m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-07-29 | 37.3 | 657 | 619.7 | – | – | – | – | 30 |
| 2025-Q4 | 2026-01-28 | 40.8 | 834.2 | 793.4 | 13.2 | 46.3 | 5.1 | 41.2 | 26 |
| 2025-Q3 | 2025-11-05 | 38.9 | 853 | 814.1 | 13.2 | 53.7 | 5.2 | 48.5 | 24 |
| 2025-Q2 | 2025-07-30 | 33.9 | 881.1 | 847.2 | 13.1 | 29.1 | 5.7 | 23.4 | 22 |
| 2025-Q1 | 2025-04-30 | 35.5 | 891.4 | 856 | 12.9 | 41.5 | 3.8 | 37.8 | 20 |
| 2024-Q4 | 2025-02-05 | 24.5 | 905.1 | 880.6 | 12.9 | 43.3 | 4 | 39.3 | 118 |
| 2024-Q3 | 2024-10-30 | 38.5 | 940.1 | 901.6 | 13 | 51.2 | 3.4 | 47.8 | 16 |
| 2024-Q2 | 2024-07-31 | 28.9 | 965.2 | 936.3 | 12.8 | 43.3 | 3.6 | 39.7 | 13 |
| 2024-Q1 | 2024-04-24 | 33.9 | 990.1 | 956.3 | 12.6 | 29.1 | 2 | 27.1 | 11 |
| 2023-Q4 | 2024-01-31 | 24.3 | 973.1 | 948.8 | 13 | 56.4 | 4.9 | 51.5 | 109 |
| 2023-Q3 | 2023-10-25 | 30.5 | 942.2 | 911.7 | 12.6 | 46.1 | 5.4 | 40.7 | 7 |
| 2023-Q2 | 2023-07-26 | 27.8 | 971.5 | 943.6 | 13 | 26.7 | 4.5 | 22.1 | 5 |
| 2023-Q1 | 2023-04-26 | 26.5 | 995.3 | 968.8 | 12.9 | -3.8 | 4.3 | -8.1 | 3 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Advertisement
Revenue by Type (as of 2026-Q2 · USDm · 6/6)#
Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.
| Segment | Since | Period | Basis | Revenue | Growth | Source |
|---|---|---|---|---|---|---|
| Single-use Products | 2023-Q1 | 2026-Q1 | 3M | 270 | -2.3% | 29 |
| Domestic | 2023-Q1 | 2026-Q1 | 3M | 173 | -5.8% | 28 |
| General Surgery | 2023-Q1 | 2026-Q1 | 3M | 169.3 | -7.4% | 29 |
| Orthopedic Surgery | 2023-Q1 | 2026-Q1 | 3M | 147.7 | 6.8% | 29 |
| International | 2023-Q1 | 2026-Q1 | 3M | 144 | 4.7% | 28 |
| Capital Products | 2023-Q1 | 2026-Q1 | 3M | 47 | 4.6% | 29 |
Advertisement
Products & M&A (2/5 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| AirSeal Robotic Solution indication for Intuitive da Vinci 5 | 2026-07 | Launched | 31 |
| Manufacturing and supply agreement for gastroenterology products | 2026-06 | Launched | 30 |
| Biliary product expansion | 2024-09 | Launched | 17 |
| BioBrace product growth (4×) | 2024-06 | Launched | 17 |
| Warehouse management system implementation | 2023 | Launched | 8 |
Advertisement
M&A (15)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions · 3Divestitures/exits · 9older: 3 (in the table)
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Repurchase of $645.2 million principal amount of 2.250% Convertible Notes | 2026-06 | Completed | 30 |
| Biorez acquisition contingent consideration payments | 2026-06 | Completed | 30 |
| Buffalo Filter acquisition | 2024 | Completed | 19 |
| 2.250% Convertible Notes offering | 2022-06 | Completed | 19 |
| In2Bones acquisition (2×) | 2022 | Completed | 17 |
| Biorez acquisition | 2022 | Completed | 19 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Sale of additional gastroenterology assets recorded as business sale in Q2 2026 | 2026-06 | Divested | 30 |
| Sale of certain gastroenterology assets | 2026-04 | Divested | 29 |
| Sale of gastroenterology assets in Q1 2026 | 2026-03 | Divested | 30 |
| Early termination of exclusive distribution agreement | 2026-03 | Divested | 28 |
| Divestiture of remaining gastroenterology portfolio | 2026-03 | Divested | 28 |
| Gore VIABIL biliary stent distribution agreement termination (4×) | 2026-01 | Divested | 25 |
| Gastroenterology product line exit (5×) | 2025-12 | Divested | 27 |
| Sale of product line | 2025-03 | Divested | 20 |
| Product line discontinuations and cancellations | 2025 | Divested | 27 |
Advertisement
Reported KPIs (as disclosed) (377)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-07-29 | 2026-Q2 | Write-off of deferred financing fees | $3.5 | 30 |
| 2026-07-29 | 2026-Q2 | Weighted average interest rate (three months 2026) | 2.84% | 30 |
| 2026-07-29 | 2026-Q2 | Weighted average interest rate (three months 2025) | 2.80% | 30 |
| 2026-07-29 | 2026-Q2 | Weighted average interest rate (six months 2026) | 2.80% | 30 |
| 2026-07-29 | 2026-Q2 | Weighted average interest rate (six months 2025) | 2.85% | 30 |
| 2026-07-29 | 2026-Q2 | Variable rate debt sensitivity (1% change, quarterly interest impact) | $1.7 | 30 |
| 2026-07-29 | 2026-Q2 | Total variable rate debt | $683.0 | 30 |
| 2026-07-29 | 2026-Q2 | Term A-2 Loan outstanding | $450.0 | 30 |
| 2026-07-29 | 2026-Q2 | Term A-2 Loan borrowings | $450.0 | 30 |
| 2026-07-29 | 2026-Q2 | Term A-1 Loan outstanding | $40.0 | 30 |
| 2026-07-29 | 2026-Q2 | Share repurchase authorization | $150.0 | 30 |
| 2026-07-29 | 2026-Q2 | Revolving credit facility borrowings | $193.0 | 30 |
| 2026-07-29 | 2026-Q2 | Revenue from single-use products | 86% | 30 |
| 2026-07-29 | 2026-Q2 | Remaining 2.250% Convertible Notes | $154.8 | 30 |
| 2026-07-29 | 2026-Q2 | Professional fees related to note repurchase | $1.8 | 30 |
| 2026-07-29 | 2026-Q2 | Planned 2026 share repurchases | $61.8 | 30 |
| 2026-07-29 | 2026-Q2 | Outstanding letters of credit | $1.5 | 30 |
| 2026-07-29 | 2026-Q2 | Operational optimization consulting and legal fees (Q2 2026) | $7.1 | 30 |
| 2026-07-29 | 2026-Q2 | Operational optimization consulting and legal fees (Q2 2025) | $2.5 | 30 |
| 2026-07-29 | 2026-Q2 | Operational optimization consulting and legal fees (H1 2026) | $14.6 | 30 |
| 2026-07-29 | 2026-Q2 | Operational optimization consulting and legal fees (H1 2025) | $2.9 | 30 |
| 2026-07-29 | 2026-Q2 | Operating cash flow (H1 ended June 30, 2026) | $50.6 | 30 |
| 2026-07-29 | 2026-Q2 | Operating cash flow (H1 ended June 30, 2025) | $70.7 | 30 |
| 2026-07-29 | 2026-Q2 | Net working capital | $220.3 | 30 |
| 2026-07-29 | 2026-Q2 | Net gain on sale of gastroenterology assets | $1.5 | 30 |
| 2026-07-29 | 2026-Q2 | Net borrowings on revolving credit facility | $193.0 | 30 |
| 2026-07-29 | 2026-Q2 | Manufacturing and supply agreement duration (gastroenterology) | twelve months | 30 |
| 2026-07-29 | 2026-Q2 | Loss on sale of gastroenterology assets | $4.4 | 30 |
| 2026-07-29 | 2026-Q2 | International sales percentage (H1 2026) | 47% | 30 |
| 2026-07-29 | 2026-Q2 | International sales percentage (H1 2025) | 44% | 30 |
| 2026-07-29 | 2026-Q2 | Income from note repurchase | $8.1 | 30 |
| 2026-07-29 | 2026-Q2 | IEEPA tariff refunds received | $10.2 | 30 |
| 2026-07-29 | 2026-Q2 | Gore distribution agreement termination benefit | $1.9 | 30 |
| 2026-07-29 | 2026-Q2 | Gastroenterology sales (Q2 2026) | $4.7 | 30 |
| 2026-07-29 | 2026-Q2 | Gastroenterology sales (Q2 2025) | $25.3 | 30 |
| 2026-07-29 | 2026-Q2 | Gastroenterology sales (H1 2026) | $14.1 | 30 |
| 2026-07-29 | 2026-Q2 | Gastroenterology sales (H1 2025) | $50.3 | 30 |
| 2026-07-29 | 2026-Q2 | Gain on sale of product offering (Q2 2026) | $1.9 | 30 |
| 2026-07-29 | 2026-Q2 | Gain on sale of product offering (H1 2026) | $5.9 | 30 |
| 2026-07-29 | 2026-Q2 | Gain on extinguishment of 2.250% Notes | $4.6 | 30 |
| 2026-07-29 | 2026-Q2 | Effective tax rate (Q2 2026) | 26.4% | 30 |
| 2026-07-29 | 2026-Q2 | Effective tax rate (Q2 2025) | 28.4% | 30 |
| 2026-07-29 | 2026-Q2 | Effective tax rate (H1 2026) | 25.8% | 30 |
| 2026-07-29 | 2026-Q2 | Effective tax rate (H1 2025) | 27.0% | 30 |
| 2026-07-29 | 2026-Q2 | EU Medical Device Regulations compliance costs (Q2 2026) | $1.1 | 30 |
| 2026-07-29 | 2026-Q2 | EU Medical Device Regulations compliance costs (H1 2026) | $2.3 | 30 |
| 2026-07-29 | 2026-Q2 | Dividends paid (H1 2025) | $12.4 | 30 |
| 2026-07-29 | 2026-Q2 | Contingent consideration (Biorez acquisition, H1 2026) | $28.9 | 30 |
| 2026-07-29 | 2026-Q2 | Contingent consideration (Biorez acquisition, H1 2025) | $14.1 | 30 |
| 2026-07-29 | 2026-Q2 | Consulting engagement charge (Q2 2025) | $5.1 | 30 |
| 2026-07-29 | 2026-Q2 | Consulting engagement charge (H1 2025) | $8.5 | 30 |
| 2026-07-29 | 2026-Q2 | Common stock repurchases | $43.2 | 30 |
| 2026-07-29 | 2026-Q2 | Common stock repurchased (shares) | 1.0 | 30 |
| 2026-07-29 | 2026-Q2 | Common stock repurchased (aggregate value incl. excise tax) | $43.7 | 30 |
| 2026-07-29 | 2026-Q2 | Cash used in financing activities (six months ended June 30, 2026) | $68.8 | 30 |
| 2026-07-29 | 2026-Q2 | Cash used in financing activities (six months ended June 30, 2025) | $54.9 | 30 |
| 2026-07-29 | 2026-Q2 | Cash proceeds from sale of gastroenterology assets | $21.5 | 30 |
| 2026-07-29 | 2026-Q2 | Capital expenditures (six months ended June 30, 2026) | $5.8 | 30 |
| 2026-07-29 | 2026-Q2 | Capital expenditures (six months ended June 30, 2025) | $9.5 | 30 |
| 2026-07-29 | 2026-Q2 | Available borrowings on revolving credit facility | $455.5 | 30 |
| 2026-07-29 | 2026-Q2 | Annual minimum share repurchases | $25.0 | 30 |
| 2026-07-29 | 2026-Q2 | Advisory services compensation (former CFO) | $3.3 | 30 |
| 2026-07-29 | 2026-Q2 | Advisory services compensation (former CEO, six months 2025) | $12.2 | 30 |
| 2026-07-29 | 2026-Q2 | Adjusted EBITDA Margin (Q2 2026) | 22.7% | 31 |
| 2026-07-29 | 2026-Q2 | Adjusted EBITDA Margin (Q2 2025) | 20.0% | 31 |
| 2026-07-29 | 2026-Q2 | Adjusted EBITDA Margin (6M 2026) | 20.4% | 31 |
| 2026-07-29 | 2026-Q2 | Adjusted EBITDA Margin (6M 2025) | 19.6% | 31 |
| 2026-07-29 | 2026-Q2 | 2.250% Notes repurchased (principal) | $645.2 | 30 |
| 2026-07-29 | 2026-Q2 | 2.250% Notes repurchase (cash consideration) | $637.2 | 30 |
| 2026-07-29 | 2026-Q2 | 2.250% Convertible Notes maturity date | June 15, 2027 | 30 |
| 2026-07-29 | 2026-Q2 | 2.250% Convertible Notes issued | $800.0 | 30 |
| 2026-04-30 | 2026-Q1 | Weighted average interest rate | 2.62% | 29 |
| 2026-04-30 | 2026-Q1 | Total shares repurchased under program | 0.9 million shares | 29 |
| 2026-04-30 | 2026-Q1 | Total amount repurchased under program | $37.4 | 29 |
| 2026-04-30 | 2026-Q1 | Term loan borrowings outstanding | $40.0 | 29 |
| 2026-04-30 | 2026-Q1 | Single-use products sales | $270.0 | 29 |
| 2026-04-30 | 2026-Q1 | Selling and administrative expense | $141.7 | 29 |
| 2026-04-30 | 2026-Q1 | Revolving credit facility borrowings outstanding | $25.0 | 29 |
| 2026-04-30 | 2026-Q1 | Research and development expense | $16.3 | 29 |
| 2026-04-30 | 2026-Q1 | Planned share repurchases for 2026 | $61.8 | 29 |
| 2026-04-30 | 2026-Q1 | Outstanding convertible notes principal | $800.0 | 29 |
| 2026-04-30 | 2026-Q1 | Orthopedic surgery sales | $147.7 | 29 |
| 2026-04-30 | 2026-Q1 | Orthopedic surgery percentage of sales | 47% | 29 |
| 2026-04-30 | 2026-Q1 | Net working capital | $377.9 | 29 |
| 2026-04-30 | 2026-Q1 | Net sales | $317.0 | 29 |
| 2026-04-30 | 2026-Q1 | Net cash used in financing activities | -$22.6 | 29 |
| 2026-04-30 | 2026-Q1 | Net cash provided by operating activities | $13.5 | 29 |
| 2026-04-30 | 2026-Q1 | Net borrowings on revolving line of credit | $25.0 | 29 |
| 2026-04-30 | 2026-Q1 | Letters of credit set aside | $1.6 | 29 |
| 2026-04-30 | 2026-Q1 | International sales percentage | 45% | 29 |
| 2026-04-30 | 2026-Q1 | Interest expense | $7.1 | 29 |
| 2026-04-30 | 2026-Q1 | Income from operations | $25.4 | 29 |
| 2026-04-30 | 2026-Q1 | Income before income taxes | $18.3 | 29 |
| 2026-04-30 | 2026-Q1 | Gross profit margin | 57.9% | 29 |
| 2026-04-30 | 2026-Q1 | General surgery sales | $169.3 | 29 |
| 2026-04-30 | 2026-Q1 | General surgery percentage of sales | 53% | 29 |
| 2026-04-30 | 2026-Q1 | Gastroenterology sales Q1 2026 | $9.5 | 29 |
| 2026-04-30 | 2026-Q1 | Effective tax rate | 24.7% | 29 |
| 2026-04-30 | 2026-Q1 | Convertible notes interest rate | 2.250% | 29 |
| 2026-04-30 | 2026-Q1 | Contingent consideration paid - Biorez | $11.4 | 29 |
| 2026-04-30 | 2026-Q1 | Common stock repurchases | $37.0 | 29 |
| 2026-04-30 | 2026-Q1 | Capital products sales | $47.0 | 29 |
| 2026-04-30 | 2026-Q1 | Capital expenditures | $2.9 | 29 |
| 2026-04-30 | 2026-Q1 | Available borrowings on revolving credit facility | $623.4 | 29 |
| 2026-04-30 | 2026-Q1 | Annual share repurchase target | $25.0 | 29 |
| 2026-04-29 | 2026-Q1 | Operating Income Margin (reported) | 8.0% | 28 |
| 2026-04-29 | 2026-Q1 | Operating Income Margin (adjusted) | 13.1% | 28 |
| 2026-04-29 | 2026-Q1 | Gross Profit Margin (reported) | 57.9% | 28 |
| 2026-04-29 | 2026-Q1 | Gross Profit Margin (adjusted) | 57.4% | 28 |
| 2026-04-29 | 2026-Q1 | Effective Tax Rate (reported) | 24.7% | 28 |
| 2026-04-29 | 2026-Q1 | Effective Tax Rate (adjusted) | 24.2% | 28 |
| 2026-04-29 | 2026-Q1 | EBITDA Margin | 14.0% | 28 |
| 2026-04-29 | 2026-Q1 | Adjusted EBITDA Margin | 17.8% | 28 |
| 2026-02-17 | FY2025 | Weighted average interest rate on borrowings 2025 | 2.79% | 27 |
| 2026-02-17 | FY2025 | Weighted average interest rate on borrowings 2024 | 3.15% | 27 |
| 2026-02-17 | FY2025 | Total cash | 40.8 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Term loan facility borrowings | 40.0 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Stock-based compensation expense 2025 | 28.3 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Stock-based compensation expense 2024 | 25.6 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Stock-based compensation expense 2023 | 24.3 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Single-use products % of revenues | 86% | 27 |
| 2026-02-17 | FY2025 | Shares repurchased under Prior Program | 6.1 | 27 |
| 2026-02-17 | FY2025 | Shares repurchased amount | 162.6 | 27 |
| 2026-02-17 | FY2025 | Sales in local currency % 2025 | 32% | 27 |
| 2026-02-17 | FY2025 | Orthopedic surgery % 2025 | 42% | 27 |
| 2026-02-17 | FY2025 | Operational optimization consulting fees | 12.9 | 27 |
| 2026-02-17 | FY2025 | Net working capital | 357.8 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Modified repurchase program | 150.0 | 27 |
| 2026-02-17 | FY2025 | International sales % 2025 | 44% | 27 |
| 2026-02-17 | FY2025 | Interest rate sensitivity | 0.4 | 27 |
| 2026-02-17 | FY2025 | Gore distribution agreement termination benefit | 9.9 | 27 |
| 2026-02-17 | FY2025 | General surgery % 2025 | 58% | 27 |
| 2026-02-17 | FY2025 | Former CEO compensation and advisory services | 12.2 | 27 |
| 2026-02-17 | FY2025 | Foreign subsidiaries cash | 29.3 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Foreign currency exchange positive impact 2025 | 1.9 | 27 |
| 2026-02-17 | FY2025 | Export basis sales in USD % | 12% | 27 |
| 2026-02-17 | FY2025 | Effective tax rate 2025 | 33.8% | 27 |
| 2026-02-17 | FY2025 | Effective tax rate 2024 | 18.8% | 27 |
| 2026-02-17 | FY2025 | Contingent consideration - In2Bones | 2.2 | 27 |
| 2026-02-17 | FY2025 | Contingent consideration - Biorez | 59.2 | 27 |
| 2026-02-17 | FY2025 | Consultant engagement costs | 12.5 (USD in millions) | 27 |
| 2026-02-17 | FY2025 | Available borrowings on revolving credit facility | 648.5 | 27 |
| 2026-02-17 | FY2025 | 2.250% Convertible Notes due 2027 | 800.0 | 27 |
| 2026-01-28 | 2025-Q4 | EBITDA Margin Q4 2025 | 14.9% | 26 |
| 2026-01-28 | 2025-Q4 | EBITDA Margin Q4 2024 | 20.4% | 26 |
| 2026-01-28 | 2025-Q4 | EBITDA Margin FY 2025 | 12.8% | 26 |
| 2026-01-28 | 2025-Q4 | EBITDA Margin FY 2024 | 20.8% | 26 |
| 2026-01-28 | 2025-Q4 | Adjusted EBITDA Margin Q4 2025 | 21.5% | 26 |
| 2026-01-28 | 2025-Q4 | Adjusted EBITDA Margin Q4 2024 | 23.1% | 26 |
| 2026-01-28 | 2025-Q4 | Adjusted EBITDA Margin FY 2025 | 20.1% | 26 |
| 2026-01-28 | 2025-Q4 | Adjusted EBITDA Margin FY 2024 | 20.3% | 26 |
| 2025-11-06 | 2025-Q3 | Single-use products % of revenue | approximately 86% | 25 |
| 2025-11-06 | 2025-Q3 | Operating cash flow (9 months 2025) | $124.4 million | 25 |
| 2025-11-06 | 2025-Q3 | Net working capital | $347.5 million | 25 |
| 2025-11-06 | 2025-Q3 | International sales percentage | 43% | 25 |
| 2025-11-06 | 2025-Q3 | Gore VIABIL gross profit margin | approximately 38% | 25 |
| 2025-11-06 | 2025-Q3 | Gore VIABIL distribution revenue (9 months 2025) | $44.1 million | 25 |
| 2025-11-06 | 2025-Q3 | Capital expenditures (9 months 2025) | $14.7 million | 25 |
| 2025-11-06 | 2025-Q3 | Available borrowings on revolving credit facility | $648.5 million | 25 |
| 2025-11-05 | 2025-Q3 | Adjusted operating income % | 15.1 (USD %) | 24 |
| 2025-11-05 | 2025-Q3 | Adjusted EBITDA Margin | 19.4 | 24 |
| 2025-07-31 | 2025-Q2 | Working capital | 362.9 (USD millions) | 23 |
| 2025-07-31 | 2025-Q2 | Term loan outstanding | 85.0 (USD millions) | 23 |
| 2025-07-31 | 2025-Q2 | Revolving credit borrowings | 4.0 | 23 |
| 2025-07-31 | 2025-Q2 | Operating cash flow | 70.7 (USD millions) | 23 |
| 2025-07-31 | 2025-Q2 | Capital expenditures | 9.5 (USD millions) | 23 |
| 2025-07-31 | 2025-Q2 | Available revolving credit | 644.4 | 23 |
| 2025-05-01 | 2025-Q1 | Weighted average interest rate | 2.90 % | 21 |
| 2025-05-01 | 2025-Q1 | Single-use products % of revenue | 86 % | 21 |
| 2025-05-01 | 2025-Q1 | Shares repurchased through March 31, 2025 | 6.1 million | 21 |
| 2025-05-01 | 2025-Q1 | Share repurchase program authorized | 200.0 million | 21 |
| 2025-05-01 | 2025-Q1 | Remaining available for share repurchases | 37.4 million | 21 |
| 2025-05-01 | 2025-Q1 | Orthopedic surgery product line percentage | 43 % | 21 |
| 2025-05-01 | 2025-Q1 | Net working capital | 355.9 million | 21 |
| 2025-05-01 | 2025-Q1 | International sales percentage | 43 % | 21 |
| 2025-05-01 | 2025-Q1 | Gross profit margin | 55.3 % | 21 |
| 2025-05-01 | 2025-Q1 | General surgery product line percentage | 57 % | 21 |
| 2025-05-01 | 2025-Q1 | Effective tax rate | 21.3 % | 21 |
| 2025-05-01 | 2025-Q1 | Available borrowings on revolving credit facility | 583.4 million | 21 |
| 2025-05-01 | 2025-Q1 | Amount repurchased through March 31, 2025 | 162.6 million | 21 |
| 2025-04-30 | 2025-Q1 | Operating Income Margin | 5.0% | 20 |
| 2025-04-30 | 2025-Q1 | Gross Profit Margin | 55.3% | 20 |
| 2025-04-30 | 2025-Q1 | Effective Tax Rate | 21.3% | 20 |
| 2025-04-30 | 2025-Q1 | EBITDA Margin | 10.6% | 20 |
| 2025-04-30 | 2025-Q1 | Adjusted Operating Income Margin | 14.1% | 20 |
| 2025-04-30 | 2025-Q1 | Adjusted Gross Profit Margin | 56.4% | 20 |
| 2025-04-30 | 2025-Q1 | Adjusted Effective Tax Rate | 23.1% | 20 |
| 2025-04-30 | 2025-Q1 | Adjusted EBITDA Margin | 19.1% | 20 |
| 2025-02-18 | FY2024 | Total debt outstanding | $914.6 million | 19 |
| 2025-02-18 | FY2024 | Single-use products % of revenues | 85% | 19 |
| 2025-02-18 | FY2024 | Royalty expense 2024 | $6.8 million | 19 |
| 2025-02-18 | FY2024 | Royalty expense 2023 | $5.3 million | 19 |
| 2025-02-18 | FY2024 | Royalty expense 2022 | $3.2 million | 19 |
| 2025-02-18 | FY2024 | Research and development 2024 | $54.4 million | 19 |
| 2025-02-18 | FY2024 | Research and development 2023 | $52.6 million | 19 |
| 2025-02-18 | FY2024 | Research and development 2022 | $47.2 million | 19 |
| 2025-02-18 | FY2024 | Orthopedic surgery single-use products percentage 2024 | 77% | 19 |
| 2025-02-18 | FY2024 | Orthopedic surgery revenue percentage | 42% | 19 |
| 2025-02-18 | FY2024 | Orthopedic surgery percentage 2023 | 43% | 19 |
| 2025-02-18 | FY2024 | Orthopedic surgery percentage 2022 | 44% | 19 |
| 2025-02-18 | FY2024 | International sales percentage 2024 | 43% | 19 |
| 2025-02-18 | FY2024 | International sales percentage 2023 | 44% | 19 |
| 2025-02-18 | FY2024 | International sales percentage 2022 | 45% | 19 |
| 2025-02-18 | FY2024 | International sales local currency percentage 2024 | 32% | 19 |
| 2025-02-18 | FY2024 | International sales export basis USD percentage 2024 | 11% | 19 |
| 2025-02-18 | FY2024 | General surgery single-use products percentage 2024 | 91% | 19 |
| 2025-02-18 | FY2024 | General surgery revenue percentage | 58% | 19 |
| 2025-02-18 | FY2024 | General surgery percentage 2023 | 57% | 19 |
| 2025-02-18 | FY2024 | General surgery percentage 2022 | 56% | 19 |
| 2025-02-18 | FY2024 | EtO sterilized products percentage 2024 | 31% | 19 |
| 2025-02-18 | FY2024 | Employees in operations | 2,400 | 19 |
| 2025-02-18 | FY2024 | Debt as percentage of total capitalization | 48% | 19 |
| 2025-02-18 | FY2024 | Capital products percentage of revenues | 15% | 19 |
| 2025-02-18 | FY2024 | Availability under senior credit agreement | $583.4 million | 19 |
| 2025-02-05 | 2024-Q4 | Operating Income Margin (Q4 2024) | 15.2% | 18 |
| 2025-02-05 | 2024-Q4 | Operating Income Margin (Q4 2023) | 15.3% | 18 |
| 2025-02-05 | 2024-Q4 | Operating Income Margin (FY 2024) | 15.3% | 18 |
| 2025-02-05 | 2024-Q4 | Operating Income Margin (FY 2023) | 9.7% | 18 |
| 2025-02-05 | 2024-Q4 | Gross Profit Margin (Q4 2024) | 57.3% | 18 |
| 2025-02-05 | 2024-Q4 | Gross Profit Margin (Q4 2023) | 55.7% | 18 |
| 2025-02-05 | 2024-Q4 | Gross Profit Margin (FY 2024) | 56.1% | 18 |
| 2025-02-05 | 2024-Q4 | Gross Profit Margin (FY 2023) | 54.3% | 18 |
| 2025-02-05 | 2024-Q4 | Effective Tax Rate (Q4 2024) | 22.7% | 18 |
| 2025-02-05 | 2024-Q4 | Effective Tax Rate (Q4 2023) | 18.7% | 18 |
| 2025-02-05 | 2024-Q4 | Effective Tax Rate (FY 2024) | 18.8% | 18 |
| 2025-02-05 | 2024-Q4 | Effective Tax Rate (FY 2023) | 20.3% | 18 |
| 2025-02-05 | 2024-Q4 | EBITDA Margin (Q4 2024) | 20.4% | 18 |
| 2025-02-05 | 2024-Q4 | EBITDA Margin (Q4 2023) | 20.9% | 18 |
| 2025-02-05 | 2024-Q4 | EBITDA Margin (FY 2024) | 20.8% | 18 |
| 2025-02-05 | 2024-Q4 | EBITDA Margin (FY 2023) | 15.5% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Operating Income Margin (Q4 2024) | 18.6% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Operating Income Margin (Q4 2023) | 15.8% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Operating Income Margin (FY 2024) | 15.5% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Operating Income Margin (FY 2023) | 14.0% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Gross Profit Margin (Q4 2024) | 57.6% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Gross Profit Margin (Q4 2023) | 56.4% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Gross Profit Margin (FY 2024) | 56.3% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Gross Profit Margin (FY 2023) | 55.2% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Effective Tax Rate (Q4 2024) | 26.7% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Effective Tax Rate (Q4 2023) | 24.2% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Effective Tax Rate (FY 2024) | 24.1% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted Effective Tax Rate (FY 2023) | 23.0% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted EBITDA Margin (Q4 2024) | 23.1% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted EBITDA Margin (Q4 2023) | 20.5% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted EBITDA Margin (FY 2024) | 20.3% | 18 |
| 2025-02-05 | 2024-Q4 | Adjusted EBITDA Margin (FY 2023) | 18.9% | 18 |
| 2024-10-31 | 2024-Q3 | Weighted average interest rate (3 months) | 3.15% | 17 |
| 2024-10-31 | 2024-Q3 | Weighted average interest rate (9 months) | 3.18% | 17 |
| 2024-10-31 | 2024-Q3 | Term loan facility borrowings | 114.6 million | 17 |
| 2024-10-31 | 2024-Q3 | Single-use products % of sales | 85% | 17 |
| 2024-10-31 | 2024-Q3 | Revolving credit facility borrowings | 36.0 million | 17 |
| 2024-10-31 | 2024-Q3 | Orthopedic surgery sales % | 41% | 17 |
| 2024-10-31 | 2024-Q3 | OCF (9 months) | 123.6 million | 17 |
| 2024-10-31 | 2024-Q3 | Net working capital | 358.7 million | 17 |
| 2024-10-31 | 2024-Q3 | International sales percentage | 43% | 17 |
| 2024-10-31 | 2024-Q3 | General surgery sales % | 59% | 17 |
| 2024-10-31 | 2024-Q3 | Effective tax rate (3 months) | 13.2% | 17 |
| 2024-10-31 | 2024-Q3 | Effective tax rate (9 months) | 17.4% | 17 |
| 2024-10-31 | 2024-Q3 | Available borrowings on revolving credit facility | 547.4 million | 17 |
| 2024-10-30 | 2024-Q3 | Operating margin | 20.7% | 16 |
| 2024-10-30 | 2024-Q3 | Operating income | 65,707 (USD in thousands) | 16 |
| 2024-10-30 | 2024-Q3 | Net sales | 316,701 (USD in thousands) | 16 |
| 2024-10-30 | 2024-Q3 | Gross profit margin | 56.5% | 16 |
| 2024-10-30 | 2024-Q3 | EBITDA Margin | 26.4% | 16 |
| 2024-10-30 | 2024-Q3 | EBITDA | 83,681 (USD in thousands) | 16 |
| 2024-10-30 | 2024-Q3 | Diluted EPS | 1.57 | 16 |
| 2024-08-01 | 2024-Q2 | Working capital | 357.4 million | 14 |
| 2024-08-01 | 2024-Q2 | Term loan outstanding | 114.6 million | 14 |
| 2024-08-01 | 2024-Q2 | Single-use products % | 84% | 14 |
| 2024-08-01 | 2024-Q2 | Shares repurchased | 6.1 million | 14 |
| 2024-08-01 | 2024-Q2 | Share repurchase remaining | 37.4 million | 14 |
| 2024-08-01 | 2024-Q2 | Share repurchase completed | 162.6 million | 14 |
| 2024-08-01 | 2024-Q2 | Share repurchase authorization total | 200.0 million | 14 |
| 2024-08-01 | 2024-Q2 | Revolving credit outstanding | 62.0 million | 14 |
| 2024-08-01 | 2024-Q2 | Operating cash flow H1 | 72.4 million | 14 |
| 2024-08-01 | 2024-Q2 | International sales % | 44% | 14 |
| 2024-08-01 | 2024-Q2 | Capex H1 | 5.6 million | 14 |
| 2024-08-01 | 2024-Q2 | Available borrowings | 521.4 million | 14 |
| 2024-04-25 | 2024-Q1 | Single-use products % of revenues | 85% | 12 |
| 2024-04-25 | 2024-Q1 | Orthopedic surgery % of consolidated net sales | 43% | 12 |
| 2024-04-25 | 2024-Q1 | International sales % of consolidated net sales | 44% | 12 |
| 2024-04-25 | 2024-Q1 | General surgery % of consolidated net sales | 57% | 12 |
| 2024-02-28 | FY2023 | Weighted average interest rate on borrowings | 3.12% | 10 |
| 2024-02-28 | FY2023 | Variable rate long-term debt | 116.6 million | 10 |
| 2024-02-28 | FY2023 | Term loan borrowings outstanding | 114.6 million | 10 |
| 2024-02-28 | FY2023 | Stock-based compensation expense | 24.3 million | 10 |
| 2024-02-28 | FY2023 | Single-use products overall | 83% | 10 |
| 2024-02-28 | FY2023 | Single-use products - Orthopedic | 76% | 10 |
| 2024-02-28 | FY2023 | Single-use products - General Surgery | 89% | 10 |
| 2024-02-28 | FY2023 | Shares repurchased | 6.1 million | 10 |
| 2024-02-28 | FY2023 | Share repurchase authorization | 200.0 million | 10 |
| 2024-02-28 | FY2023 | Selling and administrative expense as % of net sales | 40.4% | 10 |
| 2024-02-28 | FY2023 | Royalty expense 2023 | 5.3 million | 10 |
| 2024-02-28 | FY2023 | Royalty expense 2022 | 3.2 million | 10 |
| 2024-02-28 | FY2023 | Royalty expense 2021 | 2.0 million | 10 |
| 2024-02-28 | FY2023 | Revolving credit facility borrowings | 2.0 million | 10 |
| 2024-02-28 | FY2023 | Research and development expense as % of net sales | 4.2% | 10 |
| 2024-02-28 | FY2023 | Research and development expense 2023 | 52.6 million | 10 |
| 2024-02-28 | FY2023 | Research and development expense 2022 | 47.2 million | 10 |
| 2024-02-28 | FY2023 | Research and development expense 2021 | 43.6 million | 10 |
| 2024-02-28 | FY2023 | Remaining repurchase authorization | 37.4 million | 10 |
| 2024-02-28 | FY2023 | Operating cash flow | 125.3 million | 10 |
| 2024-02-28 | FY2023 | Net working capital | 304.9 million | 10 |
| 2024-02-28 | FY2023 | International sales percentage | 32% | 10 |
| 2024-02-28 | FY2023 | International sales - percentage of total | 44% | 10 |
| 2024-02-28 | FY2023 | Gross profit margin | 54.3% | 10 |
| 2024-02-28 | FY2023 | Foreign cash held by subsidiaries | 19.7 million | 10 |
| 2024-02-28 | FY2023 | Effective income tax rate | 20.3% | 10 |
| 2024-02-28 | FY2023 | Debt outstanding | 986.6 million | 10 |
| 2024-02-28 | FY2023 | Debt as percentage of total capitalization | 54% | 10 |
| 2024-02-28 | FY2023 | Contingent consideration - In2Bones | 41.4 million | 10 |
| 2024-02-28 | FY2023 | Contingent consideration - Biorez | 128.8 million | 10 |
| 2024-02-28 | FY2023 | Cash on hand | 24.3 million | 10 |
| 2024-02-28 | FY2023 | Capital products | 17% | 10 |
| 2024-02-28 | FY2023 | Available borrowings on revolving credit facility | 581.4 million | 10 |
| 2024-02-28 | FY2023 | Availability under senior credit agreement | 581.4 million | 10 |
| 2024-02-28 | FY2023 | Amount spent on repurchases | 162.6 million | 10 |
| 2023-10-26 | 2023-Q3 | Weighted average interest rate (Q3 2023) | 3.17% | 8 |
| 2023-10-26 | 2023-Q3 | Weighted average interest rate (Q3 2022) | 2.66% | 8 |
| 2023-10-26 | 2023-Q3 | Weighted average interest rate (9M 2023) | 3.13% | 8 |
| 2023-10-26 | 2023-Q3 | Weighted average interest rate (9M 2022) | 2.44% | 8 |
| 2023-10-26 | 2023-Q3 | Term loan borrowings | 134.6 million | 8 |
| 2023-10-26 | 2023-Q3 | Single-use products % of revenues | 84% | 8 |
| 2023-10-26 | 2023-Q3 | Shares repurchased to date | 6.1 million | 8 |
| 2023-10-26 | 2023-Q3 | Share repurchase program authorization | 200.0 million | 8 |
| 2023-10-26 | 2023-Q3 | Selling and administrative expense as % of sales (Q3 2023) | 41.1% | 8 |
| 2023-10-26 | 2023-Q3 | Selling and administrative expense as % of sales (Q3 2022) | 41.7% | 8 |
| 2023-10-26 | 2023-Q3 | Selling and administrative expense as % of sales (9M 2023) | 42.0% | 8 |
| 2023-10-26 | 2023-Q3 | Selling and administrative expense as % of sales (9M 2022) | 41.9% | 8 |
| 2023-10-26 | 2023-Q3 | Revolving credit facility borrowings | 22.0 million | 8 |
| 2023-10-26 | 2023-Q3 | Research and development expense as % of sales (Q3 2023) | 4.1% | 8 |
| 2023-10-26 | 2023-Q3 | Research and development expense as % of sales (Q3 2022) | 4.6% | 8 |
| 2023-10-26 | 2023-Q3 | Research and development expense as % of sales (9M 2023) | 4.2% | 8 |
| 2023-10-26 | 2023-Q3 | Research and development expense as % of sales (9M 2022) | 4.4% | 8 |
| 2023-10-26 | 2023-Q3 | Remaining available for share repurchases | 37.4 million | 8 |
| 2023-10-26 | 2023-Q3 | Orthopedic surgery percentage of net sales (Q3) | 41% | 8 |
| 2023-10-26 | 2023-Q3 | Orthopedic surgery percentage of net sales (9M) | 43% | 8 |
| 2023-10-26 | 2023-Q3 | Net working capital | 249.3 million | 8 |
| 2023-10-26 | 2023-Q3 | International sales percentage (9M 2023) | 44% | 8 |
| 2023-10-26 | 2023-Q3 | International sales percentage (9M 2022) | 45% | 8 |
| 2023-10-26 | 2023-Q3 | Gross profit margin (Q3 2023) | 55.2% | 8 |
| 2023-10-26 | 2023-Q3 | Gross profit margin (Q3 2022) | 55.1% | 8 |
| 2023-10-26 | 2023-Q3 | Gross profit margin (9M 2023) | 53.8% | 8 |
| 2023-10-26 | 2023-Q3 | Gross profit margin (9M 2022) | 55.3% | 8 |
| 2023-10-26 | 2023-Q3 | General surgery % of net sales (Q3) | 59% | 8 |
| 2023-10-26 | 2023-Q3 | General surgery % of net sales (9M) | 57% | 8 |
| 2023-10-26 | 2023-Q3 | Available borrowings on revolving credit facility | 561.4 million | 8 |
| 2023-10-26 | 2023-Q3 | Amount spent on share repurchases to date | 162.6 million | 8 |
| 2023-10-25 | 2023-Q3 | Adjusted EBITDA Margin (Three Months Ended September 30, 2023) | 19.6% | 7 |
| 2023-10-25 | 2023-Q3 | Adjusted EBITDA Margin (Nine Months Ended September 30, 2023) | 18.4% | 7 |
| 2023-07-27 | 2023-Q2 | Weighted average interest rates - three months | 3.09% | 6 |
| 2023-07-27 | 2023-Q2 | Weighted average interest rates - six months | 3.11% | 6 |
| 2023-07-27 | 2023-Q2 | Term loan borrowings outstanding | 134.6 million | 6 |
| 2023-07-27 | 2023-Q2 | Shares repurchased to date | 6.1 million | 6 |
| 2023-07-27 | 2023-Q2 | Selling and administrative expense - three months | 40.8% | 6 |
| 2023-07-27 | 2023-Q2 | Selling and administrative expense - six months | 42.4% | 6 |
| 2023-07-27 | 2023-Q2 | Revolving credit facility borrowings | 54.0 million | 6 |
| 2023-07-27 | 2023-Q2 | Research and development expense - three months | 4.3% | 6 |
| 2023-07-27 | 2023-Q2 | Research and development expense - six months | 4.3% | 6 |
| 2023-07-27 | 2023-Q2 | Repurchase program remaining | 37.4 million | 6 |
| 2023-07-27 | 2023-Q2 | Repurchase program cost to date | 162.6 million | 6 |
| 2023-07-27 | 2023-Q2 | Net working capital position | 262.4 million | 6 |
| 2023-07-27 | 2023-Q2 | Net cash from operating activities | 22.8 million | 6 |
| 2023-07-27 | 2023-Q2 | Letters of credit | 1.6 million | 6 |
| 2023-07-27 | 2023-Q2 | Interest expense - three months | 3.1% | 6 |
| 2023-07-27 | 2023-Q2 | Interest expense - six months | 3.3% | 6 |
| 2023-07-27 | 2023-Q2 | Income from operations - three months | 8.6% | 6 |
| 2023-07-27 | 2023-Q2 | Income from operations - six months | 6.5% | 6 |
| 2023-07-27 | 2023-Q2 | Gross profit margin - three months | 53.7% | 6 |
| 2023-07-27 | 2023-Q2 | Gross profit margin - six months | 53.2% | 6 |
| 2023-07-27 | 2023-Q2 | Effective tax rate - three months | 21.2% | 6 |
| 2023-07-27 | 2023-Q2 | Effective tax rate - six months | 21.7% | 6 |
| 2023-07-27 | 2023-Q2 | Available borrowings on revolving facility | 529.4 million | 6 |
| 2023-04-26 | 2023-Q1 | Operating Income Margin | 4.3% | 3 |
| 2023-04-26 | 2023-Q1 | Gross Profit Margin | 52.6% | 3 |
| 2023-04-26 | 2023-Q1 | EBITDA Margin | 10.4% | 3 |
| 2023-04-26 | 2023-Q1 | Adjusted EBITDA Margin | 17.3% | 3 |
Advertisement
Guidance Tracking (latest per metric/period · 9/15)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
Actuals: revenue in $m · EPS in $ per share · ratios in %
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-07-29 | EPS (non-GAAP) | 4.48–4.6 | – | pending | raised | 31 |
| FY2026 | 2026-07-29 | Net Sales Growth, As Reported | -1.2–-0.1% | – | pending | confirmed | 31 |
| FY2026 | 2026-07-29 | Net Sales Growth, Constant Currency | -1.7–-0.7% | – | pending | confirmed | 31 |
| FY2026 | 2026-07-29 | Net Sales Growth, Organic Constant Currency | 5–6% | – | pending | confirmed | 31 |
| FY2026 | 2026-04-29 | Gastroenterology Product Sales | 14.5–17.5 | – | pending | cut | 28 |
| FY2026 | 2026-01-28 | Revenue | 1,358–1,373 | – | pending | confirmed | 31 |
| FY2026 | 2026-01-28 | Organic Constant Currency Growth | 4.5–6% | – | pending | initiated | 26 |
| FY2025 | 2025-04-30 | EPS (non-GAAP) | 4.48–4.53 | 4.59 | beat | confirmed | 24 |
| FY2025 | 2025-02-05 | Revenue | 1,365–1,372 | 1,374.7 | beat | confirmed | 24 |
| FY2024 | 2024-07-31 | Revenue | 1,300–1,305 | 1,307 | beat | cut | 16 |
| FY2024 | 2024-07-31 | EPS (non-GAAP) | 4–4.05 | 4.17 | beat | raised | 16 |
| 2024-Q3 | 2024-10-04 ° | Revenue | 315–318 | 316.7 | in line | confirmed | 15 |
| 2024-Q3 | 2024-10-04 ° | EPS (non-GAAP) | 9–11% | 1.05 | miss | raised | 15 |
| FY2023 | 2023-07-26 | Revenue | 1,240–1,260 | 1,244.7 | in line | raised | 7 |
| FY2023 | 2023-07-26 | EPS (non-GAAP) | 3.45–3.55 | 3.45 | in line | raised | 7 |
Advertisement
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2026
In the first half of fiscal year 2026, CONMED reported net sales of $317.0 million in Q1 and $343.5 million in Q2, with Q1 declining 1.3% year-over-year and Q2 growing 0.3%, both affected by the exit of certain gastroenterology product lines effective January 1, 2026 28 30. Excluding the gastroenterology exits, organic constant currency sales grew 6.0% in Q2 2026 31. Gross profit margins expanded approximately 250-260 basis points year-over-year in both quarters, reaching 57.9% in Q1 and 57.5% in Q2, supported by the termination of the Gore distribution arrangement, favorable foreign currency impact, and product mix shifts 28 30. The orthopedic surgery segment posted sales growth of 8.2% in Q2 2026, while the general surgery segment declined primarily due to the gastroenterology product exits 30. During Q2 2026, the company repurchased $645.2 million principal of its 2.250% Convertible Notes for $637.2 million cash and updated full-year 2026 guidance to net sales of $1,358-$1,373 million and adjusted diluted EPS of $4.48-$4.60 30 31.
FY2025
CONMED's full-year 2025 net sales rose 5.2% as reported (5.1% in constant currency) to $1,374.7 million, with growth in both orthopedic surgery (5.6%) and general surgery (4.9%) product lines and sequential acceleration from +2.9% in Q1 to +7.9% in Q4 26 27. Full-year adjusted diluted EPS increased to $4.59 from $4.17 in 2024, while GAAP net income fell sharply to $47.1 million from $132.4 million in 2024, as selling and administrative expenses rose to 43.1% of net sales from 36.6%, driven by advisory compensation for the former CEO, a $64.0 million swing in contingent consideration fair value from $41.0 million income in 2024 to $23.0 million expense in 2025, and operational optimization consulting costs 27. Gross profit margin contracted 1.5 percentage points to 54.6%, primarily reflecting $12.5 million in supply chain consulting charges and $22.2 million in inventory write-offs for cancelled product lines 27. Operating cash flow increased slightly to $170.7 million from $167.0 million despite lower net income, supported by favorable working capital timing and lower interest expense as weighted average borrowings and rates declined 27. The Board suspended the quarterly dividend in October 2025, authorized a $150 million share repurchase program, and in December 2025 the company announced its intent to exit gastroenterology product lines, including termination of the Gore VIABIL biliary stent distribution agreement effective January 1, 2026 24 27.
FY2024
CONMED reported full-year 2024 net sales of $1,307.0 million, an increase of 5.0% year-over-year as reported and 5.3% in constant currency, with domestic revenue growing 6.9% and international revenue increasing 2.6% as reported, driven by growth in both orthopedic surgery and general surgery product lines 18 19. The Single-use Products segment grew 7.1% for the full year while the Capital Products segment declined 5.5%, with approximately 85% of revenues derived from single-use products 18 19. Full-year gross profit margin expanded 180 basis points to 56.1% primarily due to favorable product mix, adjusted diluted EPS increased 20.9% to $4.17, and adjusted EBITDA rose to $265.6 million from $235.4 million in 2023 18 19. Free cash flow reached $153.9 million and net debt stood at $880.6 million at year-end, with the remaining $70.0 million of 2.625% Notes repaid in February 2024 18 19. Persistent supply chain challenges and hurricane-related manufacturing disruptions were navigated throughout the year, concluding with a planned leadership transition as Patrick Beyer was announced as incoming President and CEO effective January 1, 2025, succeeding retiring CEO Curt Hartman 16 17 18.
FY2023
CONMED Corporation reported full-year 2023 net sales of $1,244.7 million, a 19.1% increase from $1,045.5 million in 2022, with acquisitions of In2Bones Global and Biorez contributing approximately 250 basis points of growth 9 10. The company returned to profitability with net income of $64.5 million compared to a net loss of $80.6 million in 2022, aided by a reduction in selling and administrative expenses as a percentage of net sales from 43.4% to 40.4% 9 10. Gross margin was 54.3% in 2023, down 0.3 percentage points from 2022, as inflation in raw materials, freight, and production costs offset volume-related gains 10. Operating cash flow improved significantly to $125.3 million from $33.4 million in the prior year, while net debt stood at $948.8 million at year-end 10 18. Revenue growth decelerated from 21.9% in Q1 to 10.7% in Q3 before re-accelerating to 30.4% in Q4, supported by warehouse management system improvements and organic demand across product lines 3 7 9.
Advertisement
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
46 documents · 2016 – 2026 · SEC EDGAR (USA)
| # | Document type | Published | Link |
|---|---|---|---|
| #1 / #101 | 8-K-EX99.1 | 2023-02-02 | Open |
| #2 | 10-K | 2023-02-21 | Open |
| #3 | 8-K-EX99.1 | 2023-04-26 | Open |
| #4 | 10-Q | 2023-04-27 | Open |
| #5 / #105 | 8-K-EX99.1 | 2023-07-26 | Open |
| #6 | 10-Q | 2023-07-27 | Open |
| #7 / #107 | 8-K-EX99.1 | 2023-10-25 | Open |
| #8 | 10-Q | 2023-10-26 | Open |
| #9 / #109 | 8-K-EX99.1 | 2024-01-31 | Open |
| #10 | 10-K | 2024-02-28 | Open |
| #11 / #111 | 8-K-EX99.1 | 2024-04-24 | Open |
| #12 | 10-Q | 2024-04-25 | Open |
| #13 | 8-K-EX99.1 | 2024-07-31 | Open |
| #14 | 10-Q | 2024-08-01 | Open |
| #15 | 8-K-EX99.1 | 2024-10-04 | Open |
| #16 | 8-K-EX99.1 | 2024-10-30 | Open |
| #17 | 10-Q | 2024-10-31 | Open |
| #18 / #118 | 8-K-EX99.1 | 2025-02-05 | Open |
| #19 | 10-K | 2025-02-18 | Open |
| #20 | 8-K-EX99.1 | 2025-04-30 | Open |
| #21 | 10-Q | 2025-05-01 | Open |
| #22 | 8-K-EX99.1 | 2025-07-30 | Open |
| #23 | 10-Q | 2025-07-31 | Open |
| #24 | 8-K-EX99.1 | 2025-11-05 | Open |
| #25 | 10-Q | 2025-11-06 | Open |
| #26 | 8-K-EX99.1 | 2026-01-28 | Open |
| #27 | 10-K | 2026-02-17 | Open |
| #28 | 8-K-EX99.1 | 2026-04-29 | Open |
| #29 | 10-Q | 2026-04-30 | Open |
| #30 | 10-Q | 2026-07-29 | Open |
| #31 | 8-K-EX99.1 | 2026-07-29 | Open |
Older sources (+15)
| # | Document type | Published | Link |
|---|---|---|---|
| #202 | 10-K | 2016-05-02 | Open |
| #201 | 10-Q | 2016-07-28 | Open |
| #204 | 10-K | 2017-02-27 | Open |
| #206 | 10-K | 2017-02-27 | Open |
| #203 | 10-Q | 2017-07-27 | Open |
| #205 | 10-Q | 2018-08-02 | Open |
| #208 | 10-K | 2019-02-25 | Open |
| #207 | 10-Q | 2019-08-01 | Open |
| #212 | 10-K | 2020-02-24 | Open |
| #209 | 10-Q | 2020-04-30 | Open |
| #210 | 10-Q | 2020-07-30 | Open |
| #211 | 10-Q | 2020-10-29 | Open |
| #213 | 10-Q | 2021-04-29 | Open |
| #214 | 10-Q | 2021-07-29 | Open |
| #215 | 10-Q | 2021-10-28 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including EPS (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Does Conmed Corporation pay a dividend?
The filings report on the dividend; most recent entry: dividends paid $12.4 (2026-Q2) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Conmed Corporation?
The sources chapter links all 52 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.
More reports#
Recently updated
Advertisement